Patricia Inácio, PhD, science writer —

Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein, reduces the rate of attacks in hereditary angioedema (HAE) patients by more than 70%, a Phase 2 study shows. Also, more patients receiving the prophylactic, or preventive, treatment remained without an attack during the study’s four-week duration. The study,…

Delays in the diagnosis of hereditary angioedema causes family caregivers to feel fear, anxiety, and uncertainty, according to a study focused on better understanding what these caregivers go through during the diagnosis process. Giving attention and credibility to family caregivers could not only improve understanding and awareness of the disease but…

KVD900, a potential new approach for treating hereditary angioedema, prevents the breakdown of kininogen and subsequent buildup of bradykinin — the underlying cause of the disease, KalVista Pharmaceuticals announced. The company confirmed this mechanism of action using a new test that measures the amounts of high molecular weight kininogen in the plasma. The…

Comparing the genetic profile of patients with hereditary angioedema during remission and in acute attacks, researchers identified two genes that seem to participate in edema formation. The genes – uPAR and ADM – are involved in vessel dilation and inflammation, and may be potential therapeutic targets for the disease. The…

A Phase 3 trial testing BCX7353, an inhibitor of plasma kallikrein for the prevention of swelling attacks in hereditary angioedema (HAE) patients, has dosed its first participant, BioCryst Pharmaceuticals announced. The trial, APeX-2, will include roughly 100 patients with type 1 and type 2 hereditary angioedema in several centers in the…

Lanadelumab, an antibody that binds and inhibits plasma kallikrein, effectively reduces the number of swelling attacks and improves quality-of-life scores in patients with hereditary angioedema (HAE) when used as a preventive treatment, new data from the Phase 3 HELP study shows. The findings, which support the clinical benefits of lanadelumab as…

A long-term clinical trial testing BCX7353’s ability to prevent hereditary angioedema (HAE) attacks is dosing its first group of participants, BioCryst Pharmaceuticals announced. “Initiation of the APeX-S trial is an important milestone to support filing and approval of BCX7353, and furthers our core strategy of bringing a once-daily, oral prophylactic…

Long-term treatment with human plasma-derived C1 inhibitor may help women with hereditary angioedema get pregnant and carry out the pregnancy to full term without risking complications, a case report suggests. The study, from a hospital in Valencia, Spain, titled, “Successful long-term prophylaxis with human plasma-derived C1 inhibitor in…

The biopharmaceutical company Shire is expected to soon submit a biologics license application to the U.S. Food and Drug Administration (FDA) seeking marketing approval of its investigational monoclonal antibody lanadelumab as therapy for patients with hereditary angioedema. The application is supported by positive results from the company’s Phase 3 HELP…